|
Real-time Estimate
Cboe BZX
15:13:07 2026-10-20 EDT
|
5-day change | 1st Jan Change | ||
| 799.14 USD | +2.19% |
|
+6.10% | +3.52% |
| 09:01am | AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial | RE |
| 10-19 | Major drugmakers turn to China for licensing deals | RE |
| Market Cap | 78.09B 69.51B 64.42B 58.38B 110B 7,398B 112B 773B 304B 3,871B 293B 287B 12,350B | P/E 2026 * |
16.8x | P/E 2027 * | 15.3x |
|---|---|---|---|---|---|
| Enterprise Value | 70.49B 62.74B 58.15B 52.69B 99.03B 6,677B 101B 698B 274B 3,494B 264B 259B 11,148B | EV / Sales 2026 * |
4.02x | EV / Sales 2027 * | 3.61x |
| Free-Float |
71.06% | Yield 2026 * |
0.5% | Yield 2027 * | 0.55% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| REGN | Delayed | |
CBOE
| REGN | Real-time | |
|
Mexican S.E.
| REGN * | End-of-day quote | |
|
Tradegate
| RGO | Real-time | |
|
Xetra
| RGO | End-of-day quote | |
|
Boerse Muenchen
| RGO | Real-time | |
|
London S.E.
| 0R2M | Delayed | |
|
Börse Stuttgart
| RGO | Delayed | |
|
Borsa Italiana
| 1REGN | End-of-day quote | |
|
Deutsche Boerse AG
| RGO | Delayed | |
|
Wiener Boerse
| REGN | End-of-day quote | |
|
Lima
| REGNUS | End-of-day quote |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +2.19% | ||
| 1 week | +5.82% | ||
| Current month | +5.10% | ||
| 1 month | -0.16% | ||
| 3 months | +18.56% | ||
| 6 months | +6.34% | ||
| Current year | +3.25% |
| 1 week | 755.21 |  | 809.49 |
| 1 month | 722.02 | | 813.53 |
| Current year | 591.52 | | 859.34 |
| 1 year | 572.75 | | 859.34 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 2000-12-31 | |
| Chief Executive Officer | 73 | 1988-01-07 | |
| Director of Finance/CFO | 55 | 2024-02-04 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 2023-06-08 | |
Joseph Goldstein
BRD | Director/Board Member | 85 | 1991-05-31 |
George Sing
BRD | Director/Board Member | 76 | 1988-01-07 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/14/26 | Sell | Chief Technology Officer | -4,147 | 0.0041% | ||
| 9/3/26 | Sell | Executive/Senior Manager | -1,131 | 0.0011% | ||
| 9/2/26 | Exercice | Director | 1,200 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.19% | +5.82% | +38.17% | -1.43% | 78.09B | |
| +4.44% | +11.09% | +60.20% | +121.66% | 1,106B | |
| +2.39% | +4.22% | +33.74% | +69.34% | 612B | |
| +2.85% | +5.76% | +25.03% | +98.42% | 500B | |
| +2.58% | +8.37% | +38.71% | +63.14% | 367B | |
| +3.30% | +4.18% | +71.36% | +44.07% | 354B | |
| +1.85% | +6.04% | +21.47% | +49.17% | 286B | |
| +1.76% | +6.07% | +0.43% | +20.98% | 256B | |
| +2.73% | +5.50% | +43.58% | +56.21% | 230B | |
| +1.97% | +5.18% | +26.37% | +99.97% | 190B | |
| Average | +2.52% | +2.17% | +35.91% | +62.15% | 397.82B | |
| Weighted average by Cap. | +2.96% | +2.30% | +41.09% | +79.46% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.54B 15.61B 14.47B 13.11B 24.64B 1,662B 25.05B 174B 68.21B 870B 65.79B 64.43B 2,774B | 18.59B 16.55B 15.33B 13.9B 26.12B 1,761B 26.55B 184B 72.28B 922B 69.73B 68.28B 2,940B |
| Net income | 5.27B 4.69B 4.35B 3.94B 7.4B 499B 7.53B 52.17B 20.5B 261B 19.77B 19.36B 834B | 5.55B 4.94B 4.58B 4.15B 7.79B 526B 7.93B 54.92B 21.57B 275B 20.81B 20.38B 877B |
| Net Debt | -7.6B -6.77B -6.27B -5.68B -10.68B -720B -10.86B -75.26B -29.57B -377B -28.52B -27.93B -1,202B | -10.97B -9.76B -9.05B -8.2B -15.41B -1,039B -15.67B -109B -42.65B -544B -41.14B -40.29B -1,735B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-20 | US$799.51 | +2.23% | 345,206 |
| 26-10-19 | US$782.04 | -1.10% | 489,580 |
| 26-10-16 | US$790.74 | -0.70% | 653,725 |
| 26-10-15 | US$796.34 | +2.31% | 798,909 |
| 26-10-14 | US$778.36 | +3.35% | 879,091 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
